tbuckley/cabot-search huggingface dataset:
Re: Raj Satkunasivam, Sheaumei Tsai, Sumeet Syan, et al. Robotic Unclamped “Minimal-margin” Partial Nephrectomy: Ongoing Refinement of the Anatomic Zero-ischemia Concept. Eur Urol 2015;68:705–12
Authors: Steven C. Campbell, Gopal N. Gupta, Robert G. Uzzo, Alexander Kutikov
Journal: European Urology (2015)
Milk as Transport Agent for Diethylnitrosamine in Syrian Golden Hamsters2
Authors: R. Spielhoff, H. Bresch, M. Hönig, U. Mohr
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Milk as Transport Agent for Diethylnitrosamine in Syrian Golden Hamsters Get access R. Spielhoff, R. Spielhoff Search for other works by this author on: Oxford Academic PubMed Google Scholar H. Bresch, H. Bresch Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Hönig, M. Hönig Search for other works by this author on: Oxford Academic PubMed Google Scholar U. Mohr U. Mohr 3Abteilung fur Experimentelle Pathologie, Medizinische Hochschule Hannover, 3000 Hannover-Klcefeld, KarlWiechert- Allee 9, West Germany. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 1, July 1974, Pages 281–282, https://doi.org/10.1093/jnci/53.1.281 Published: 01 July 1974 Article history Received: 11 March 1974 Accepted: 19 March 1974 Published: 01 July 1974
Longitudinal assessment of cognitive impairment among lung cancer survivors
Authors: S. Kohli, D. W. Szydlo, P. J. Novotny, P. Yang, P. D. Brown, J. C. Buckner, J. A. Sloan
Journal: Journal of Clinical Oncology (2009)

9609 Background: Patients undergoing treatment for cancer often report problems with their cognitive function (CF), which is an essential component in maintaining Quality of Life (QoL). We conducted a longitudinal study of lung cancer (LC) patients to systematically evaluate changes in QOL including changes in CF, over time. Methods: Between 2005–2008, we followed 1757 primary LC patients who responded to CF questions at least once within 8 years of diagnosis. Overall QoL measured by LCSS and LASA (scores 0–100 from worst to best) were assessed among 1,604 of 1,757 (91%) who completed the questionnaire at one or both of two time periods: short-term (T1-within 3 years of diagnosis) and long-term follow-up (T2-beyond 5 years of diagnosis). Questions rated overall CF and problems in thinking clearly. Results: The median age at the time of LC diagnosis was 68 years in men (n=834) and 65 years in women (n=770), p&lt;0.0001. At T1, the mean score of patients reporting problems with CF was 63.2 (±22.45) vs 74.4 (±20.38) who reported no problems (p&lt;0.0001). At T2, the mean score was 62.2 (±24.18) for patients who reported CF problems and 78.1 (±18.28) who reported no changes with their CF (p&lt;0.0001). At T1, the mean score of patients reporting problems thinking clearly was 66.1 (±21.65) vs 75.6 (±20.21) reporting no problems with their thinking (p&lt;0.0001). At T2, the mean score was 70.4 (±20.95) for patients reporting problems thinking clearly vs 82.6 (±17.76) who reported no problems (p&lt;0.0001). Conclusions: Self-reported QoL of lung cancer survivors showed substantial deficits with their cognitive function. Prospective and objective assessments are needed to determine if cancer treatments are positively associated with cognitive decline, to identify the patients at risk, and to test appropriate interventions. Funding Source: NIH grants: CA 115857, CA 84354, CA 80127 and CA 77118. No significant financial relationships to disclose.
<i>Pueblo Series, Acoma</i>
Authors: Jeanette M. Smith
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunologic and Virologic Status after 14 to 18 Years of Infection with an Attenuated Strain of HIV-1 — A Report from the Sydney Blood Bank Cohort
Authors: Jennifer C. Learmont, Andrew F. Geczy, John Mills, Lesley J. Ashton, Camille H. Raynes-Greenow, Roger J. Garsia, Wayne B. Dyer, Larissa McIntyre, Robert B. Oelrichs, David I. Rhodes, Nicholas J. Deacon, Dale A. McPhee, Suzanne Crowe, Ajantha E. Solomon, Catherine Chatfield, Sean Blasdall, Harmjan Kuipers, John S. Sullivan
Journal: New England Journal of Medicine (1999)

The Sydney Blood Bank Cohort consists of a blood donor and eight transfusion recipients who were infected before 1985 with a strain of human immunodeficiency virus type 1 (HIV-1) with a deletion in the region in which the nef gene and the long terminal repeat overlap. Two recipients have died since 1994, at 77 and 83 years of age, of causes unrelated to HIV infection; one other recipient, who had systemic lupus erythematosus, died in 1987 at 22 years of age of causes possibly related to HIV. We present longitudinal immunologic and virologic data on the six surviving members and one deceased member of this cohort through September 30, 1998.
Case 19-1983
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Scott T. Weiss, Eugene J. Mark
Journal: New England Journal of Medicine (1983)

Presentation of CaseA 44-year-old woman was admitted to the hospital because of respiratory failure.She was well until 19 months earlier, when a mass was noted in the right breast. Evaluation elsewhere revealed that the mass was an abscess. An x-ray film of the chest (Fig. 1) showed a reticular pattern consistent with sarcoidosis. A specimen of arterial blood, drawn while the patient was breathing room air, demonstrated that the partial pressure of oxygen (PaO2) was 75 mm Hg, and the partial pressure of carbon dioxide (PaCO2) 31 mm Hg. Pulmonary-function studies were interpreted as . . .
The Effect of Pregnancy on Gastric Secretion
Authors: W. A. Gryboski, H. M. Spiro
Journal: New England Journal of Medicine (1956)

PREGNANCY is said to alleviate the symptoms of peptic ulcer, according to numerous clinical reports.1 2 3 4 5 The availability of an indirect measure of gastric secretion by the blood pepsin method6 , 7 offered an excellent opportunity for study of the effect of pregnancy on gastric secretion. Blood pepsin levels usually parallel gastric pepsin levels and are taken to be a reflection of gastric secretory activity. This study suggests that the alleviation of duodenal ulcer by pregnancy may be related more to diet and care than to the physiologic events.MethodTwenty-one pregnant women, from eighteen to forty-two years of age, were studied in . . .
[68Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma
Authors: Kathrin Philipp-Abbrederis, Ken Herrmann, Margret Schottelius, Matthias Eiber, Carlos Gerngroß, Elke Pietschmann, Katharina Lückerath, Katharina Franke, Martina Rudelius, Stefan Knop, Katharina Götze, Kristina Schwamborn, Sabine Steidle, Ambros Beer, Christian Peschel, Hermann Einsele, Andreas Buck, Markus Schwaiger, Hans-Jürgen Wester, Ulrich Keller
Journal: Blood (2014)
Interventions to modify physical activity in patients with COPD: a systematic review
Authors: Leandro Cruz Mantoani, Noah Rubio, Brian McKinstry, William MacNee, Roberto A. Rabinovich
Journal: European Respiratory Journal (2016)

The broad range of interventions to increase physical activity (PA) in patients with chronic obstructive pulmonary disease (COPD) has not been systematically assessed. We aimed to perform a systematic review of the interventional studies that have assessed PA as an outcome in patients with COPD. A systematic search in five different databases (Medline, Embase, PsycINFO, CINAHL and Web of Science) was performed in March 2015. Two independent reviewers analysed the studies against the inclusion criteria (COPD defined by spirometry; prospective, randomised/nonrandomised studies, cohort and experimental studies with interventions using PA as an outcome), extracted the data and assessed the quality of evidence. 60 studies were included. Seven intervention groups were identified. PA counselling increased PA levels in COPD, especially when combined with coaching. 13 studies showed positive effects of pulmonary rehabilitation (PR) on PA, while seven studies showed no changes. All three PR programmes &gt;12 weeks in duration increased PA. Overall, the quality of evidence was graded as very low. Interventions focusing specifically on increasing PA, and longer PR programmes, may have greater impacts on PA in COPD. Well-designed clinical trials with objective assessment of PA in COPD patients are needed.
Methylation and silencing of the gene for the receptor-type protein tyrosine phosphatase PTPRO in primary human tumors
Authors: Tasneem M. Motiwala, Sarmila Majumder, Kalpana Ghoshal, Huban Kutay, John Byrd, Michael Grever, Samson T. Jacob
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

923 

Promoter methylation is a major mechanism for the transcriptional silencing of many tumor suppressor genes. Using Restriction Landmark Genomic Scanning technique to identify methylated genes, we found that the gene for the receptor-type protein tyrosine phosphatase receptor-type O (PTPRO) is suppressed in primary rat hepatocellular carcinoma induced by folate/methyl deficient diet, which probably occurs as a result of regional/localized hypermethylation (Motiwala, T. et.al., Oncogene, 22, 6319-6332, 2003). We further demonstrated methylation of this gene in many primary human solid tumors including hepatocellular carcinoma and lung cancer by COBRA (combined bisulfite restriction analysis) and bisulfite genomic sequencing. Real-time PCR showed that the methylated PTPRO in many tumor samples is silenced. The suppressed gene in some lung cancer cell lines could also be re-activated upon treatment with 5-aza-deoxycytidine (decitabine), a potent inhibitor of DNA methyltransferase I. Ectopic expression of the full-length isoform in a lung cancer cell line resulted in reduced proliferation, delayed re-entry into cell-cycle following release from cell-cycle arrest, increased susceptibility to apoptosis (Motiwala, T. et. al., PNAS, 101, 13844-9, 2004) and reduced tumor forming potential in nude mice. To demonstrate that the methylation-mediated suppression of PTPRO is a common characteristic of different types of cancers we analyzed a large number of primary chronic lymphocytic leukemia (CLL) samples. Normal B-lymphocytes express the truncated isoform of PTPRO (PTPROt). While the B-lymphocytes from normal individuals were free of methylation, approximately 75% (n=92) of primary CLL samples exhibited methylation at the PTPRO CpG island. Further, ectopic expression of PTPROt in leukemia cells resulted in slower growth rate and loss of anchorage-independent growth. These observations suggest that this specific receptor-type tyrosine phosphatase plays an important role in regulating growth and proliferation of mammalian cells. In addition to exhibiting these characteristics of tumor suppressor genes, the PTPRO gene is localized to chromosomal region 12p12.3 that is characterized by loss of heterozygosity in several tumor types, another hallmark of classical tumor suppressors. Protein tyrosine phosphatases are gaining recognition as important cellular molecules due to their ability to function as positive and negative regulators of signal transduction pathways involved in different cellular processes. Identification of PTPRO as a candidate tumor suppressor, therefore, provides a novel molecular target in cancer therapy. Further, its expression could also be used as a prognostic marker in cancer therapy. Supported, in part, by grants CA 81024, CA86978, and ES 10874 (STJ) from the National Institutes of Health.
Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy
Authors: Fatima el Bahhaj, Iza Denis, Loic Pichavant, Régis Delatouche, Floraine Collette, Camille Linot, Daniel Pouliquen, Marc Grégoire, Valérie Héroguez, Christophe Blanquart, Philippe Bertrand
Journal: Theranostics (2016)

Fast clearance, metabolism and systemic toxicity are major limits for the clinical use of anti-cancer drugs.Histone deacetylase inhibitors (HDACi) present these defects despite displaying promising anti-tumor properties on tumor cells in vitro and in in vivo model of cancers.Specific delivery of anti-cancer drugs into the tumor should improve their clinical benefit by limiting systemic toxicity and by increasing the anti-tumor effect.In this work, we describe a simple and flexible polymeric nanoparticle platform highly targeting the tumor in vivo and triggering impressive tumor weight reduction when functionalized with HDACi.Our nanoparticles were produced by Ring-Opening Metathesis Polymerization of azido-polyethylene oxide-norbornene macromonomers and functionalized using click chemistry.Using an orthotopic model of peritoneal invasive cancer, a highly selective accumulation of the particles in the tumor was obtained.A combination of epigenetic drugs involving a pH-responsive histone deacetylase inhibitor (HDACi) polymer conjugated to these particles gave 80% reduction of tumor weight without toxicity whereas the free HDACi has no effect.Our work demonstrates that the use of a nanovector with theranostic properties leads to an optimized delivery of potent HDACi in tumor and then, to an improvement of their anti-tumor properties in vivo.
Epirubicin, cisplatin, oral UFT (ECU) combination chemotherapy in metastatic gastric carcinoma
Authors: S. Kaya, M. Aliustaoglu, F. Dane, M. Gumus, M. Seker, A. Ozturk, T. Salepci, M. Yaylaci, A. Mayadagli
Journal: Journal of Clinical Oncology (2007)

15126 Background: Chemotherapy significantly improves survival in comparison to best supportive care in patients with metastatic gastric cancer. In patients for whom a three-drug-combination is considered as the treatment of choice, ECF (epirubicin, cisplatin and 5-FU as a continuous infusion) should be regarded as standard of care. Continuous 5-FU infusion may be replaced by oral fluoropyrimidines. Here, we aimed to evaluate treatment with epirubicin and cisplatin combined with oral UFT with leucovorin (ECU), replacing intravenous 5-FU infusion Methods: Fifty-three patients (17 female, 36 male) with metastatic gastric carcinoma received epirubicin, cisplatin, and oral UFT plus leucovorin in two outpatient chemotherapy clinics, in Istanbul. Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 were administered on day 1; and UFT 300 mg/m2/day was administered in conjunction with oral calcium folinate at a fixed dose of either 45 or 90 mg/day in divided daily doses for 21 days continuously. The treatment was repeated every 3 weeks. The patients were evaluated radiologically for response after each three-cycle period. Age, gender, ECOG performance score (PS), primary cancer localization, and presence of primary curative surgery were analyzed for prognostic factors. Results: Median follow-up was 6 (range 1–12) months. Median age was 57 years (range 27–76). Patients received a median of three courses of treatment (range: 1–6). Over 86% of the patients had PS =1, whereas remaining 13% had PS 2. Forty-three percent of the patients were undergone curative surgery at the time of cancer diagnosis, while 57% presented as metastatic disease. The most frequent site of metastases was liver (42%). Twenty-five percent of the patients showed partial responses, while none showed a complete response. Over 28% of the patients had stable disease resulting in a tumor control rate of 53%, and 47% had progressive disease. Median TTP and OS were 6 and 8.6 months, respectively. In univariate analysis; having PS =1, and presence of primary curative surgery were independent prognostic factors (p:0.042, and p:0.019, respectively) Conclusion: ECU regimen has a significant activity in metastatic gastric cancer. It does not require an infusion pump and intravenous catheter. No significant financial relationships to disclose.
Use of Smokeless Tobacco in Major-League Baseball
Authors: G N Connolly, C T Orleans, M Kogan
Journal: New England Journal of Medicine (1988)

Two types of smokeless tobacco are popular among baseball players today: moist snuff, commonly referred to as "dip," and chewing tobacco. Snuff is a finely ground, processed tobacco product that is placed between the cheek and gum. Chewing tobacco is cut or compressed tobacco leaf that is sold loose or as a solid plug. In the mouth, the tobacco releases nicotine, which mixes with saliva and crosses the oral mucosa into the bloodstream.1 Chewing tobacco was very popular in the United States when the rules of organized baseball were first written in 1845. Many of the early players chewed as . . .
Abstract 3772: Alternate Listing Transplantation is a Cost-Effective Treatment for End-Stage Heart Failure Patients
Authors: Mark J Russo, Jonathan M Chen, Kimberly N Hong, Michael Argenziano, Ryan R Davies, Isaac George, Deborah D Ascheim, Alan Moskowitz, Annetine Gelijns, Mehmet C Oz, Yoshifumi Naka
Journal: Circulation (2007)

BACKGROUND: In order to offer the benefit of heart transplantation to a greater number of patients some centers match high-risk recipients (HR) with non-standard or ”marginal” donors (MD) in a strategy known as Alternate Listing Transplantation (ALT). However, pairing sicker recipients with lower quality donor organs remains both clinically and ethically controversial. The purpose of this study was to determine the cost-effectiveness of this strategy. METHODS: The United Network of Organ Sharing provided deidentified patient-level data. UNOS data was used to determine clinical outcomes, including waiting time, post-transplant survival, length of stay, re-hospitalizations, episodes of rejection, and infection, based on all adult heart transplant candidates (age [gt] 18 yo) and listed between 1995–2005 (n=35,049). Through a systematic literature review of randomized controlled trials and case series that estimated related costs, a cost model (see Table ) using an intention-to-treat assumption was developed to calculate the incremental cost-effectiveness ratio (ICER) for HR candidates who subsequently received marginal donor hearts (HTR) compared with candidates who were not transplanted (NTXP). High-risk recipient criteria included age [gt] 65yo, retransplantation, HepC+, HIV+, CrCl &lt;30 ml/min, DM with PVD, DM with Crcl &lt;40 ml/min. MD criteria included age [gt] 55yo, DM, HIV+, HepC+, EF&lt;45%, and donor:recipient weight &lt;0.7. RESULTS: Median survival from listing was 0.55 yrs and 5.1 yrs in the HTR and NTXP groups, respectively. The estimated ICER was $66,645($34,046–$127,491) ICER varied by HR recipient criteria. CONCLUSIONS: The ICER for ALT falls at the upper limits acceptability for being cost-effective. However, stratified analysis by HR group suggests that this strategy is not appropriate for all groups. Cost Model Assumptions
PTPS-12INTENSIVE CHEMOTHERAPY FOLLOWED BY REDUCED RADIATION DOSE FOR INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMORS
Authors: Teruyoshi Kageji, Yoshifumi Mizobuchi, Kohei Nakajima, Shinji Nagahiro, Hiroyoshi Watanabe, Nami Inoue, Kazumi Okamura, Shoji Kagami
Journal: Neuro-Oncology (2015)

PTPS-12. INTENSIVE CHEMOTHERAPY FOLLOWED BY REDUCED RADIATION DOSE FOR INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMORS Teruyoshi Kageji1, Yoshifumi Mizobuchi1, Kohei Nakajima1, Shinji Nagahiro1, Hiroyoshi Watanabe2, Nami Inoue2, Kazumi Okamura2, and Shoji Kagami2; Department of Neurosurgery, School of Medicine, the University of Tokushima, Tokushima, Japan; Department of Pediatrics, School of Medicine, the University of Tokushima, Tokushima, Japan PURPOSE: It is well known that an intracranial non-germinomatous germ cell tumors (NGGCT), especially the patients who demonstrated high level of serum tumor marker has poor prognosis after standard treatment of chemotherapy and whole brain and spinal radiation. The radiation for childhood can be induce significant neurodevelopmental, neuroendocrine, somatic growth, cognitive impairments and secondary tumors. The objective of this study was to determine whether intensive chemotherapy followed by reduced radiation dose is effective in patients with poor prognosis group of intracranial NGGCT. PATIENTS AND METHODS: We have treated 15 patients (mean age 17 y.o.) with poor prognosis group of an intracranial 24 NGGCTs. The serum b-HCG ranged from 0 to 151052 mIU/ml and AFP ranged from 0 to 4120 ng/ml.The NAT(neo-adjuvant therapy),which isprecedingchemotherapy before surgery, was performed in 9 patients which presented with serum b-HCG of over 500 mIU/ml or AFP 500 ng/ml. As chemo-radiotherapy, the ICE regimen (ifosfamide, cisplatin, etoposide) and whole brain (30Gy) and spinal (24Gy) irradiation was used for 9 patients of poor prognosis group from 1998 to 2006. The intensive regimen (cisplatin, etoposide, cyclophosphamide, bleomycin, carboplatin) and reduced radiotherapy (whole ventricle radiation 30Gy) have been induced for 6 patients since 2007. RESULTS: Mean follow-up period is 76 months. In ICE regimen, five of nine (56%) died (CSF dissemination: 3, secondary GBM: 1, sepsis: 1). In intensive regimen, none died and had serious complications. The initial chemotherapy achieves complete remission in 33%. The 3-year, 5-year and 10-year survival rate of all patients was 68%, 68% and 51%, respectively. The 5-year survival rate of the ICE and intensive regimen was 50% and 100%, respectively. CONCLUSION: Intensive chemotherapy followed by reduced radiation dose and field for poor prognosis group of intracranial NGGCT was safe and expected favorable prognosis and reducing or avoiding late effects. Neuro-Oncology 17:v179–v185, 2015. doi:10.1093/neuonc/nov228.12 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials
Authors: M.J. Overman, V. Morris, B. Kee, D. Fogelman, L. Xiao, C. Eng, A. Dasari, R. Shroff, T. Mazard, K. Shaw, E. Vilar, K. Raghav, I. Shureiqi, L. Liang, G.B. Mills, R.A. Wolff, S. Hamilton, F. Meric-Bernstam, J. Abbruzzese, J. Morris, D. Maru, S. Kopetz
Journal: Annals of Oncology (2016)